» Articles » PMID: 16139948

Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Specimens

Overview
Journal Eur Urol
Specialty Urology
Date 2005 Sep 6
PMID 16139948
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Purposes: To elucidate the prognostic value of the immunohistochemical (IHC) expression of Bcl-2, Bax, Cox-2 and Ki-67 antigen in biopsy cores (C) and surgical specimens (SP) of prostate cancer (PC) and to determine the C to SP reproducibility.

Material And Methods: The IHC study was carried out in 91 patients operated by means of radical prostatectomy (RP) with available formalin-fixed paraffin-embedded material from both C and SP.

Results: The IHC expression of Bcl-2 in C and SP was very low (5%). Bax was expressed in almost all the patients and did not show any prognostic value. We observed a good reproducibility between C and SP for all molecules except with Bax. In prostate C, Ki-67 and Cox-2 were considered positive in 42.9% and 67% of the patients respectively, and were related to disease-free survival in the univariate analysis. The expression of these two markers in SP was observed in 51.6% and 79.1% of the patients and the expression of Ki-67 in SP maintained its independence as prognostic factor in the multivariate analysis related to disease-free survival.

Conclusions: The IHC expression of Ki-67 and Cox-2 proteins in our study do offer valuable prognostic information, mostly the first one. Thus, we think these markers might be studied in larger series of patients for its further validation as prognostic factors in prostate biopsies.

Citing Articles

A Study of Ki-67 Immunostaining in Prostate Carcinomas and Its Correlation with Gleason's Score and Prognosis: An Experience at a Tertiary Centre in the Himalayan Foothills.

Jha N, Phulware R, Kumar A, Singh A, Durgapal P, Chowdhury N Indian J Surg Oncol. 2024; 15(2):341-348.

PMID: 38741642 PMC: 11088575. DOI: 10.1007/s13193-024-01902-4.


The In Vitro Pro-inflammatory Functions of the SP/NK1R System in Prostate Cancer: a Focus on Nuclear Factor-Kappa B (NF-κB) and Its Pro-inflammatory Target Genes.

Ebrahimi S, Erfani B, Alalikhan A, Ghorbani H, Farzadnia M, Afshari A Appl Biochem Biotechnol. 2023; 195(12):7796-7807.

PMID: 37093533 DOI: 10.1007/s12010-023-04495-w.


Targeting Lipid Peroxidation for Cancer Treatment.

Clemente S, Martinez-Costa O, Monsalve M, Samhan-Arias A Molecules. 2020; 25(21).

PMID: 33167334 PMC: 7663840. DOI: 10.3390/molecules25215144.


Clinical significance of EPHX2 deregulation in prostate cancer.

Liu M, Zhao H, Xu C, Xie P, Wang W, Yang Y Asian J Androl. 2020; 23(1):109-115.

PMID: 32687069 PMC: 7831821. DOI: 10.4103/aja.aja_34_20.


[Reports of prostate needle biopsies-what pathologists provide and urologists want].

Offermann A, Hupe M, Joerg V, Sailer V, Kramer M, Merseburger A Urologe A. 2020; 59(4):461-468.

PMID: 32016505 DOI: 10.1007/s00120-020-01121-z.